cancer screening
Lunit and Coreline Soft have been tapped to join large-scale cancer screening programs.
The proof-of-concept study published in Nature Cancer highlights how researchers are using tumor cells to predict whether patients will respond to specific drugs.
The digital cytology system helps identify cervical cancer cells and precancerous lesions using deep learning AI and volumetric imaging technology.
It signed a distribution deal with UE LifeSciences to scale the access to iBreastExam in primary care clinics.
It expects to get a contract shortly to supply its AI solutions in over 170 hospitals across the kingdom.
It will use its fresh funds to complete a multi-site validation study across eight Asia-Pacific markets.
Also, annalise.ai has made key executive appointments to support its global expansion.
They will provide the first access to an AI-enabled minimal residual disease test in India.
The company develops a breakthrough device for detecting residual cancer tissues.
Also, SeekIn is set to release an AI-based all-cancer screening test in Europe.